1
Emp-Activity: Empagliflozin Functional Capacity
Condition(s):Heart FailureLast Updated:May 13, 2022Not yet recruiting
Empagliflozin: 343 Clinical Trials, Page 1 of 35
Hide Studies Not Open or Pending
2
Empagliflozin in Acute Heart Failure
Condition(s):Acute Heart Failure; Chronic Kidney DiseasesLast Updated:March 31, 2022Not yet recruiting
3
Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B
Condition(s):Chronic Hepatitis b; NAFLD; Cirrhosis; Fibrosis, Liver; Empagliflozin; SGLT2 InhibitorsLast Updated:December 7, 2021Not yet recruiting
4
Empagliflozin Impact on Hemodynamics in Patients With Heart Failure
Condition(s):Heart FailureLast Updated:December 9, 2021Completed
5
Empagliflozin in Adolescent Diabetes
Condition(s):type1diabetesLast Updated:June 8, 2021Not yet recruiting
6
Effect of Empagliflozin on Liver Fat in Non-diabetic Patients
Condition(s):Non-alcoholic Fatty Liver DiseaseLast Updated:May 25, 2022Active, not recruiting
7
Empagliflozin in Post-Transplantation Diabetes Mellitus
Condition(s):Posttransplant Diabetes MellitusLast Updated:May 7, 2019Completed
8
Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines
Condition(s):CardiotoxicityLast Updated:March 8, 2022Not yet recruiting
9
Empagliflozin in Hypertrophic Cardiomyopathy
Condition(s):Hypertrophic Cardiomyopathy; Heart FailureLast Updated:April 12, 2022Not yet recruiting
10
Metabolic Effects of the SGLT-2 Inhibitor Empagliflozin in Patients With Diabetic Nephropathy (MEDiaN)
Condition(s):Diabetic NephropathiesLast Updated:December 17, 2020Terminated